clinical trial · NCT04878913
Retrospective Evaluation of Lung Pathology in Subjects With COVID-19
COVID-19COVID-19 PneumoniaC21Placebo
brief summary
Non-interventional, retrospective, multi-center, follow-up study evaluating the effect of C21 on lung pathology in subjects previously hospitalised with COVID-19 and enrolled in the VP-C21-006 trial.
started
Jul 7, 2021
primary completion
Aug 23, 2021
completion
Aug 23, 2021
last updated
Sep 4, 2024
detailed description
The study will collect available HRCT scans obtained prior to, during treatment with C21 or placebo and up to 24 weeks after trial completion.
HRCT scans will be assessed for ground glass opacity, reticulation, band opacity, fibrosis and consolidation by a central, blinded HRCT reader.
official title
Non-interventional, Retrospective, Multicenter, Follow-up Study Evaluating the Effect of C21 on Lung Pathology in Subjects Previously Hospitalized With COVID-19 and Enrolled in the VP-C21-006 Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol